VISCOAT Ophthalmic Viscosurgical Device; DUOVISC Ophthalmic Viscosurgical System; DISCOVISC Ophthalmic Viscosurgical
Alcon Laboratories · Decision date Oct 1, 2026
What did the FDA decide?
FDA recorded a 30-Day Notice decision coded OK30 on 2026-10-01 for PMA supplement P840064/S094 from Alcon Laboratories. The supplement covers a change in the Endotoxin testing program for the subject ophthalmic viscosurgical devices, including test article preparation and individual component testing. The listed products are VISCOAT Ophthalmic Viscosurgical Device, DUOVISC Ophthalmic Viscosurgical System and DISCOVISC Ophthalmic Viscosurgical, classified under product code LZP in the ophthalmic specialty.
The recorded reason is a process change involving a manufacturer, sterilizer, packager or supplier. This entry documents a testing-program change within the existing PMA rather than an approval of the whole device system, and the source does not specify which endotoxin test methods, acceptance limits or component-level preparations were accepted. No FDA documents were included, so the decision letter and any conditions of the OK30 action remain unavailable here.
Whether the revised endotoxin testing affects finished-device release specifications or only in-process controls is not stated in the source data, and no clinical or legal conclusions follow from this record.
FDA approval order statement
a change in the Endotoxin testing program for the subject ophthalmic viscosurgical devices (OVDs), including test article preparation and individual component testing
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Oct 1, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P840064/S094
- Regulatory pathway
- PMA supplement
- Applicant
- Alcon Laboratories
- Product code
- LZP
- Decision code
- OK30
- Decision date
- Oct 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: AID, SURGICAL, VISCOELASTIC.
- Applicant
- Alcon Laboratories
- Product code
- LZP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P840064. Subsequent supplements may change the device or its indications.
FDA decision timeline
P840064 · Original PMA
VISCOAT(TM)/DVOVISC/DISCOVISC OPHTHALMIC VISCOSURGICAL DEVICES
P840064/S094 received
Application receipt date recorded by FDA.
P840064/S094 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P840064. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P840064
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Laboratories | PMA approval | Apr 30, 1986 | FDA |
Explore the linked device profile
Other records with product code LZP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
PROVISC Ophthalmic Viscosurgical DeviceP890047/S072 | Alcon Research, Ltd. | PMA supplement | Oct 1, 2026 | FDA |
| Alcon Research, Ltd. | PMA approval | Sep 26, 1991 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA approval | Jan 14, 1983 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alcon Laboratories
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6201 S. Fwy., Fort Worth, TX, 76134
Sources and methodology
- Original FDA record: P840064/S094
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



